Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-01 (pharmaceutical-technology.com)
Biogen's Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
Biogen's CEO Chris Vibacher said 'a new Biogen' is emerging following the end of its multiple sclerosis treatments heyday.
Read more
2025-05-01 (investors.com)
Is Biogen Stock At The 'Start Of A Turnaround' On Its Quarterly Beat? | Investor's Business Daily
Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs.
Read more
2025-04-30 (tradingview.com)
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y — News
Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1.80 per share in the year-ago quarter.Revenues in the first quarter totaled $14.1 million, up from $7.9…
Read more
2025-04-29 (investing.com)
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast By
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast
Read more
2025-04-25 (marketbeat.com)
FY2027 Earnings Forecast for Biogen Issued By William Blair
Biogen Inc. (NASDAQ:BIIB - Free Report) - Research analysts at William Blair dropped their FY2027 earnings per share (EPS) estimates for Biogen in a research report issued on Wednesday, April 23rd. William Blair analyst M. Minter now forecasts that the biotechnology company will earn $16.77 per s
Read more
2025-04-03 (investing.com)
RBC Capital cuts Biogen stock price target to $221 By
On Thursday, RBC Capital Markets adjusted its financial outlook on Biogen shares, reducing the price target to $221 from $225 while maintaining an Outperform rating. According to InvestingPro data, the stock is currently trading near its 52-week low of $128.51, with analyst targets ranging from $135 to $342, suggesting significant potential upside. The company maintains a healthy financial profile with an InvestingPro Financial Health score of "GOOD." Brian Abrahams of RBC Capital Markets shared insights on Biogen's quarterly performance, noting an expectation for revenues to align closely with consensus estimates at $2.25 billion versus the $2.24 billion forecast. This comes as the company's trailing twelve-month revenue stands at $9.68 billion, with a robust gross profit margin of 76%.
Read more
2025-03-31 (nasdaq.com)
Validea Detailed Fundamental Analysis - BIIB |
Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital
Read more
2025-03-08 (morningstar.se)
5 shares with the largest reductions of estimated fair value after the Q4 result
Stmicroelectronics and Biogen are among the shares that have the largest reductions.
Read more
2025-03-07 (nasdaq.com)
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints |
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Read more
2025-03-07 (wsj.com)
Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook
Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook ... Biogen shares fell, after the biotechnology company forecast lower-than-expected...
Read more
2025-03-04 (investors.com)
Biogen Takes A Beating After Earnings Report. Here's Why.
Biogen (BIIB) stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.
Read more
2025-02-13 (asianetnews.com)
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip-
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.
Read more